Debajyoti Bhowmik

603 total citations
31 papers, 414 citations indexed

About

Debajyoti Bhowmik is a scholar working on Oncology, Hematology and Surgery. According to data from OpenAlex, Debajyoti Bhowmik has authored 31 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 11 papers in Hematology and 8 papers in Surgery. Recurrent topics in Debajyoti Bhowmik's work include Bone health and treatments (14 papers), Multiple Myeloma Research and Treatments (8 papers) and Management of metastatic bone disease (6 papers). Debajyoti Bhowmik is often cited by papers focused on Bone health and treatments (14 papers), Multiple Myeloma Research and Treatments (8 papers) and Management of metastatic bone disease (6 papers). Debajyoti Bhowmik collaborates with scholars based in United States, Switzerland and United Kingdom. Debajyoti Bhowmik's co-authors include Yi Qian, Michele Intorcia, Guy Hechmati, Menaka Bhor, Rohini K. Hernandez, Roger von Moos, Jean‐Jacques Body, A. Rider, Francesca Gatta and Amylou C. Dueck and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Pain.

In The Last Decade

Debajyoti Bhowmik

29 papers receiving 407 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Debajyoti Bhowmik United States 13 227 129 86 72 57 31 414
Grace Kranwinkel United States 5 298 1.3× 203 1.6× 59 0.7× 34 0.5× 21 0.4× 7 624
Anju Parthan United States 11 129 0.6× 81 0.6× 44 0.5× 22 0.3× 113 2.0× 38 469
J Walczak United States 11 98 0.4× 144 1.1× 34 0.4× 30 0.4× 70 1.2× 25 528
Maria Albertsson Sweden 17 504 2.2× 260 2.0× 34 0.4× 56 0.8× 305 5.4× 35 877
Parfrey Ps Canada 13 56 0.2× 79 0.6× 50 0.6× 19 0.3× 70 1.2× 24 574
Christian M. Custodio United States 9 314 1.4× 93 0.7× 47 0.5× 27 0.4× 136 2.4× 20 452
Jennifer Berano Teh United States 13 184 0.8× 56 0.4× 277 3.2× 34 0.5× 42 0.7× 26 624
Christopher Gilfillan Australia 14 106 0.5× 87 0.7× 15 0.2× 52 0.7× 97 1.7× 35 600
Knut B. Smeland Norway 12 161 0.7× 66 0.5× 36 0.4× 45 0.6× 16 0.3× 34 350
John D. Cowan United States 12 201 0.9× 61 0.5× 33 0.4× 13 0.2× 32 0.6× 20 544

Countries citing papers authored by Debajyoti Bhowmik

Since Specialization
Citations

This map shows the geographic impact of Debajyoti Bhowmik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debajyoti Bhowmik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debajyoti Bhowmik more than expected).

Fields of papers citing papers by Debajyoti Bhowmik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debajyoti Bhowmik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debajyoti Bhowmik. The network helps show where Debajyoti Bhowmik may publish in the future.

Co-authorship network of co-authors of Debajyoti Bhowmik

This figure shows the co-authorship network connecting the top 25 collaborators of Debajyoti Bhowmik. A scholar is included among the top collaborators of Debajyoti Bhowmik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debajyoti Bhowmik. Debajyoti Bhowmik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burnett, Heather, Debajyoti Bhowmik, Katharina Buesch, et al.. (2025). Comparative Efficacy of Nonstatin Lipid-Lowering Therapies in Patients With Hypercholesterolemia at Increased Cardiovascular Risk: An Updated Network Meta-Analysis. Journal of Cardiovascular Pharmacology. 86(3). 251–258. 2 indexed citations
2.
Li, Suying, Suying Li, Haifeng Guo, et al.. (2020). Discharge status and post-discharge healthcare costs after skeletal-related event hospitalizations among medicare patients with bone metastatic solid tumors or multiple myeloma. Journal of bone oncology. 26. 100328–100328. 1 indexed citations
3.
4.
Denduluri, Neelima, Gary H. Lyman, Yunfei Wang, et al.. (2018). Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. Clinical Breast Cancer. 18(5). 380–386. 54 indexed citations
5.
Body, Jean‐Jacques, Roger von Moos, A. Rider, et al.. (2018). A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe. Journal of bone oncology. 14. 100212–100212. 27 indexed citations
6.
Bhowmik, Debajyoti, et al.. (2018). Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population. Current Medical Research and Opinion. 35(3). 513–523. 18 indexed citations
7.
Bhowmik, Debajyoti, et al.. (2018). Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database. Journal of Medical Economics. 21(6). 622–628. 15 indexed citations
8.
Shi, Qiuling, Tito R. Mendoza, Amylou C. Dueck, et al.. (2017). Determination of mild, moderate, and severe pain interference in patients with cancer. Pain. 158(6). 1108–1112. 51 indexed citations
9.
Qian, Yi, et al.. (2017). Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States. Supportive Care in Cancer. 25(6). 1845–1851. 22 indexed citations
10.
Qian, Yi, et al.. (2017). Utilization of agents to prevent skeletal-related events among patients with multiple myeloma: analysis of real-world data. Supportive Care in Cancer. 26(3). 807–812. 3 indexed citations
11.
12.
Qian, Yi, et al.. (2015). Utilization Patterns of Bone-Targeting Agents Among Patients with Multiple Myeloma: Analysis of Real-World Data. Blood. 126(23). 4501–4501. 4 indexed citations
13.
Bhowmik, Debajyoti, Menaka Bhor, Brooke Middlebrook, et al.. (2015). The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting. Clinical Lymphoma Myeloma & Leukemia. 15(10). 599–605. 18 indexed citations
14.
Bhowmik, Debajyoti, Rajender R. Aparasu, Suja S. Rajan, et al.. (2014). Risk of Manic Switch Associated with Antidepressant Therapy in Pediatric Bipolar Depression. Journal of Child and Adolescent Psychopharmacology. 24(10). 551–561. 12 indexed citations
15.
Patt, Debra A., et al.. (2014). A Real-World Observational Study of Patients with Advanced Melanoma Receiving First-Line Ipilimumab in a Community Practice Setting. Journal of Cancer Therapy. 5(12). 1049–1058. 4 indexed citations
16.
17.
Sonpavde, Guru, et al.. (2014). Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 32(4_suppl). 223–223. 1 indexed citations
18.
19.
Bhowmik, Debajyoti, Rajender R. Aparasu, Suja S. Rajan, et al.. (2013). The utilization of psychopharmacological treatment and medication adherence among Medicaid enrolled children and adolescents with bipolar depression. Journal of Affective Disorders. 150(2). 424–429. 12 indexed citations
20.
Yang, Mo, Debajyoti Bhowmik, Xin Wang, & Susan Abughosh. (2012). Does combination pharmacological intervention for smoking cessation prevent post-cessation weight gain? A systemic review. Addictive Behaviors. 38(3). 1865–1875. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Grace Kranwinkel Breakdown of academic impact, for papers by Anju Parthan Breakdown of academic impact, for papers by J Walczak Breakdown of academic impact, for papers by Maria Albertsson Breakdown of academic impact, for papers by Parfrey Ps Breakdown of academic impact, for papers by Christian M. Custodio Breakdown of academic impact, for papers by Jennifer Berano Teh Breakdown of academic impact, for papers by Christopher Gilfillan Breakdown of academic impact, for papers by Knut B. Smeland Breakdown of academic impact, for papers by John D. Cowan
Rankless by CCL
2026